Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORA | P35398 | 2/20 | 0.34 |
| ▸ | RORC | P51449 | 2/20 | 0.34 |
| ▸ | RORB | Q92753 | 2/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.31 |
| ▸ | PER2 | O15055 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6921166 | 0.90 | GRIN2B (0.33) | RORARORCRORBHRH1HTR6 | |
| SCHEMBL15290458 | 0.87 | HTR6 (0.40) | RORARORCRORBHRH1HTR6 | |
| SCHEMBL17230273 | 0.84 | HTR6 (0.38) | HRH1HTR6PER2 | |
| SCHEMBL6920890 | 0.83 | HTR6 (0.39) | RORARORCRORBHRH1HTR6 | |
| SCHEMBL6921700 | 0.82 | HTR6 (0.41) | HRH1HTR6PER2SIGMAR1 | |
| SCHEMBL13394715 | 0.82 | HTR6 (0.38) | HTR6PTGDR2SIGMAR1 | |
| SCHEMBL6920556 | 0.81 | SIGMAR1 (0.33) | HRH1HTR6PTGDR2SIGMAR1 | |
| SCHEMBL6920874 | 0.80 | HTR6 (0.37) | HRH1HTR6HSD17B10PTGDR2 | |
| SCHEMBL6919939 | 0.80 | HTR6 (0.37) | HRH1HTR6HSD17B10PTGDR2 | |
| SCHEMBL6919920 | 0.80 | HTR6 (0.37) | HRH1HTR6HSD17B10PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791132-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | RORA 936/4885RORC 875/4885RORB 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.